Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.

"Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President and CEO of BioMS Medical. "Our hope is that the results of this trial will confirm that dirucotide is able to significantly slow the progression of MS, specifically in patients with secondary progressive multiple sclerosis."

Currently, BioMS is conducting two clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

        -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
           phase III trial, being conducted in Canada and Western Europe, had
           completed full recruitment of 611 SPMS patients at 47 trial sites
           in ten countries. To date, there have been nine positive safety
           reviews from the Data Safety Monitoring Board (DSMB). The primary
           clinical endpoint for MAESTRO-01 (and MAESTRO-03) is defined as a
           statistically and clinically significant increase in the time to
           progression of the disease as measured by the Expanded Disability
           Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4
           immune response genes.

           On August 13, 2008, the DSMB conducted a scheduled interim
           analysis of efficacy and safety and recommended that the trial
           continue to completion. The interim analysis evaluated the first
           200 patients to complete MAESTRO-01 and assessed the likelihood of
           the study reaching
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 The new , ... , available today on PharmaBoardroom.com for ... crisis that rocked the Spanish economy in 2009, and the ... community has remained pragmatic in times of trouble. ... the fifth biggest European market, and the general conditions to ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: ... early-stage algae bioactive compounds and metabolic processes, is pleased to ... board of directors. Ms. Nola E. Masterson , a ... joined the board effective September 17, 2014. ... to join our board," states Andrew Dahl , President ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3POCT Market in China 2014-2018 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3
... , , , , , , ... 11/1999 , , , , , , , ... Cell line , COS-1, monkey, kidney, , ... pEGFP-N1 (in bidistilled H 2 O), , , ...
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.510 12/2001 , ... , , , , , ... , Cell type , Bacteria, ...
... , , , , , , ... 915.032 03/2000 , , , , , , ... Cell line , BW 5147, mouse lymphoma T-cell line, ... Plasmid pEGFP-N1 (in bidistilled H 2 O), , ...
Cached Biology Technology:COS-1 2Corynebacterium glutamicum 2BW 5147 2
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... manipulate spoken language is unique to humans. "The genetic ... of human evolution to make this possible are largely ... now have," says Wolfgang Enard, Professor of Anthropology and ... the molecular biological basis of language Enard has now ... latest study, undertaken in collaboration with scientists at several ...
(Date:9/18/2014)... seem to be cheerful, happy-go-lucky characters, so you might ... life. , In fact some dogs are distinctly ... Sydney shows. , "This research is exciting because ... objectively and non-invasively. It offers researchers and dog owners ... that changes," said Dr Melissa Starling, from the Faculty ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... California, Davis, have invented a superthin "nanoglue" that could ... itself (say, semiconductor wafers) would break before the glue ... He and his fellow researchers have filed a provisional ... two surfaces. Pan,s nanoglue, which conducts heat and can ...
... As scientists continue the hunt for energy sources that ... amount of valuable farmland is being used to produce ... sources are renewable, economists and ecologists fear that diverting ... drive up costs. Now, Prof. Avigdor Abelson ...
... addressing the major challenges facing humanity in the 21st Century, ... Perspective published in The Plant Cell , the two ... to transforming plant biology in order to meet human needs. ... the biosphere, provide food and materials used by humans, and ...
Cached Biology News:Is seaweed the future of biofuel? 2The future of plant science a technology perspective 2
... a partial recombinant IFNA2. Immunogen: ... is produced in E. coli. The biological ... OMIM: 147562, ... MM951100564 MA Code: ABV0P9DPB ...
... 100-120 V, is used to coat the inner ... create the source of the DNA that enters ... gene gun. The station includes a tubing support ... foot Nalgene nitrogen regulator hose, two 0.1875 inch ...
... Microarray Hybridization Wash Pack provides optimized ... slides. Preparation Quality Clarifier: Ready-to-use wash ... with SigmaScreen(tm) APS Coated Slides for ... Microarray Hybridization Blocking Buffer: 1L • ...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
Biology Products: